-
BML-277: A New Frontier in Chk2 Inhibition and Genomic Stabi
2026-07-02
Explore how BML-277, a potent and selective Chk2 inhibitor, is advancing DNA damage response research and radioprotection of T-cells. This article uncovers novel mechanistic insights and practical assay guidance, setting it apart from existing resources.
-
CCG-1423: Strategic RhoA Inhibition for Oncology & Virology
2026-07-02
Discover how CCG-1423, a potent RhoA inhibitor, enables translational researchers to dissect RhoA/ROCK signaling in both cancer and viral infection models. This article blends mechanistic insights with practical guidance, drawing on recent virology findings and advanced cancer biology to inform next-generation experimental design.
-
PCI-32765 (Ibrutinib): Precision Workflows in B-Cell Researc
2026-07-01
PCI-32765 (Ibrutinib) is redefining B-cell and glioma research with nanomolar BTK inhibition and robust experimental reproducibility. This article delivers actionable workflows, advanced applications, and troubleshooting strategies for leveraging APExBIO’s trusted inhibitor in disease modeling and translational assays.
-
Ribociclib Succinate (LEE011): Precision CDK Inhibition in C
2026-07-01
Explore how Ribociclib succinate (LEE011 succinate), a potent CDK inhibitor, advances cancer research through precise cell cycle modulation and practical assay design. This article offers a unique analysis of solubility, combinatorial strategies, and evidence-based workflow optimization.
-
Capsaicin for TRPV1 and KDM1A Research: Protocols & Advances
2026-06-30
Capsaicin ((E)-Capsaicin) stands at the intersection of sensory neuroscience and cancer epigenetics, uniquely enabling dual TRPV1 activation and KDM1A inhibition. This guide details experimental workflows, troubleshooting, and innovations from recent chronic dermatitis research, empowering reproducible, high-impact results.
-
Dovitinib (TKI-258): Advanced RTK Inhibition in Cancer Model
2026-06-30
Dovitinib (TKI-258) empowers researchers to dissect RTK-driven oncogenic signaling with nanomolar potency, enabling robust apoptosis induction and pathway inhibition in diverse cancer cell models. This guide details practical workflows, protocol optimizations, and troubleshooting strategies to unlock Dovitinib’s full potential in translational cancer research.
-
Excessive Calpain Impairs Offspring Cognition via BDNF/TrkB
2026-06-29
This study uncovers how maternal non-obstetric surgery during pregnancy can elevate calpain activity in the hippocampus of rat offspring, disrupting BDNF/TrkB signaling and leading to persistent cognitive deficits. Pharmacological inhibition of calpain or activation of TrkB partially restores synaptic function and cognition, providing mechanistic clarity and experimental strategies for neuroprotection research.
-
CH 223191: Precision Aryl Hydrocarbon Receptor Antagonist Wo
2026-06-29
CH 223191 empowers researchers to dissect AhR signaling, dioxin toxicity, and epithelial regeneration with nanomolar precision. This guide delivers actionable protocols, troubleshooting strategies, and insights into leveraging CH 223191—particularly in models of intestinal repair and environmental toxicology.
-
Alternariol in Mycotoxin Research: Protocols and Troubleshoo
2026-06-28
Alternariol (AOH) is a gold-standard probe for unraveling mycotoxin-induced liver fibrosis and cytochrome P450 metabolism. This article guides researchers through practical workflows, troubleshooting, and advanced applications, leveraging APExBIO's research-grade Alternariol for robust, reproducible results.
-
Trifluoperazine 2HCl: Applied Workflows for Dopamine D2 Modu
2026-06-27
Trifluoperazine 2HCl stands out as a benchmark dopamine D2 receptor inhibitor for dissecting dopaminergic signaling in neuropharmacology and immunology. This article translates cutting-edge research and practical troubleshooting into actionable protocols, enabling robust experimental design from bench neuroscience to host-pathogen interaction studies.
-
MLKL Polymerization Drives Necroptosis via Lysosomal Catheps
2026-06-26
This study uncovers how MLKL polymerization at lysosomal membranes induces permeabilization, leading to the cytosolic release of cathepsin B and execution of necroptosis. Targeting cathepsin B with selective inhibitors offers a new precision approach for dissecting cell death pathways in disease models.
-
AC008406.3 Knockdown Sensitizes Breast Cancer to Docetaxel v
2026-06-26
This study identifies the long non-coding RNA AC008406.3 as a regulator of cuproptosis and a modulator of docetaxel sensitivity in breast cancer cells. Targeting AC008406.3 enhances the anti-tumor effects of docetaxel by promoting cuproptosis, offering a potential new therapeutic avenue.
-
CA-074: Cathepsin B Inhibitor for Precision Oncology and Pla
2026-06-25
Explore how CA-074, a selective cathepsin B inhibitor, advances research in cancer metastasis and plant senescence. This article uniquely bridges molecular oncology and plant biology, providing deep technical insights and practical assay guidance.
-
Phalloidin (B7678): Technical Guide for F-Actin Visualizatio
2026-06-25
Phalloidin (B7678) is a cyclic heptapeptide toxin optimized for high-affinity binding and stabilization of filamentous actin (F-actin) in fixed or permeabilized samples. It addresses the need for reliable cytoskeleton visualization in static cell and tissue preparations but is not suited for live-cell assays or experiments requiring reversible actin dynamics.
-
Screening FDA Drugs Reveals Lopinavir as MERS-CoV Inhibitor
2026-06-24
The reference study systematically screened FDA-approved compounds, identifying four with significant activity against MERS-CoV, including Lopinavir (ABT-378). These findings provide a potential pathway for rapid repurposing of existing antivirals and inform future research on cross-pathogen therapeutic strategies.